InvestorsHub Logo
Followers 22
Posts 996
Boards Moderated 0
Alias Born 08/01/2016

Re: None

Wednesday, 08/17/2016 3:01:06 PM

Wednesday, August 17, 2016 3:01:06 PM

Post# of 4493
HERE IS WHAT'S COMING: ( added Dr. Selick. "Beyond evofosfamide, we continue to make progress with our two Phase 2 proof-of-concept trials of tarloxotinib, our hypoxia-activated EGFR tyrosine kinase inhibitor, and plan to share preliminary results of those clinical trials in MID-2016." )

Fourth Quarter and Year End 2015 Financial Results

-- As of December 31, 2015 and 2014, Threshold had $48.7 million and $58.6

million in cash, cash equivalents and marketable securities,

respectively.

MID 2016 is now !

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTEM News